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In-silico trial of intracranial flow diverters
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The cost of clinical trials is ever-increasing. In-silico trials rely on virtual populations and
interventions simulated using patient-specific models and may offer a solution to lower these
costs. We present the flow diverter performance assessment (FD-PASS) in-silico trial, which
models the treatment of intracranial aneurysms in 164 virtual patients with 82 distinct
anatomies with a flow-diverting stent, using computational fluid dynamics to quantify post-
treatment flow reduction. The predicted FD-PASS flow-diversion success rates replicate the
values previously reported in three clinical trials. The in-silico approach allows broader
investigation of factors associated with insufficient flow reduction than feasible in a con-
ventional trial. Our findings demonstrate that in-silico trials of endovascular medical devices
can: (i) replicate findings of conventional clinical trials, and (ii) perform virtual experiments
and sub-group analyses that are difficult or impossible in conventional trials to discover new
insights on treatment failure, e.g. in the presence of side-branches or hypertension.
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Recent developments in patient-specific computationalsimulations have enabled in-silico trials to predict thesafety and efficacy of novel drugs, medical devices or other
treatments as part of the research and development life-cycle1,2.
Some of the benefits of in-silico trials include: (i) enabling more
evidence to be obtained before bench or animal studies are
started; (ii) extending the trial cohort to rare, extreme or difficult-
to-recruit patient phenotypes; (iii) directly comparing two alter-
native treatments in the same virtual population (reducing the
observed effect variance); (iv) evaluating devices under practically
challenging physiological conditions that could represent extreme
but plausible applications (off-label use); and (v) reducing
the number of animals and humans required in trials, and the
refinement of long-term studies to minimise suffering3. Drug and
device regulatory authorities, such as the FDA, are working
with the biomedical modelling and simulation community to
specify the requirements for introducing evidence obtained from
in-silico trials into the regulatory process or informing the design
of conventional trials4.
Leveraging on the recent understanding and developments of
in-silico trials, here for the first time, we use an exemplar medical
device in-silico trial to: (i) determine whether in-silico trials can
replicate outcomes of conventional clinical trials using indepen-
dent simulated populations that match those of actual clinical
trials; and (ii) in the event of successful replication, demonstrate
whether such virtual trials can facilitate exploratory virtual
experiments not easily achievable in conventional clinical trials,
thus providing new insights and generating new hypotheses.
We investigated these aims in the flow diverter (FD) perfor-
mance assessment (FD-PASS) study, an exemplar in-silico trial
for the treatment of intracranial aneurysms using FDs. An FD is a
braided, self-expanding, stent-like device implanted through a
catheter at the site of a wide-necked cerebral aneurysm. Its
function is to reduce blood flow into the aneurysm, instigating the
natural formation of an intrasaccular thrombus and blood clot-
ting, eventually leading to a complete eradication of the aneur-
ysm. With over 100,000 cases treated with FDs after their first
FDA approval in 2011, these devices revolutionised management
of the intracranial aneurysms. Several clinical trials and studies
have demonstrated that flow diversion is a safe and effective
treatment for many types of aneurysms; however, there are some
issues regarding flow diversion failure that have yet to be fully
elucidated. Although multiple types of FDs are available in Eur-
ope, only the Pipeline Embolization Device (Medtronic) and the
Surpass Streamline Flow Diverter (Stryker) are currently FDA
approved in the United States5. The PED is the oldest and the
most well-studied FD and, to date, no other FDs have been shown
to outperform the PED. We, therefore, chose to base our in-silico
trial on FDs, and the PED in particular, to determine whether
FD-PASS can replicate and expand the substantial knowledge
acquired from almost a decade of clinical trials and studies on this
device.
FDs are primarily used to treat uncoilable, large/giant and
wide-neck aneurysms of the internal carotid artery (ICA). How-
ever, large/giant aneurysms represent a small fraction of all
intracranial aneurysms, as approximately 80% of all unruptured
aneurysms are small-/medium-sized (≤10 mm)6. Recent trials
showed the promise of high occlusion rates in small-/medium-
sized, but wide-necked, aneurysms treated with FDs7,8. Hence,
the FD-PASS trial included wide-neck (≥4 mm), unruptured
aneurysms arising from the ICA. This criterion was applied on
patient-specific simulation-ready 3D surface models of saccular
intracranial aneurysms from the @neurIST project9 to generate
the FD-PASS in-silico trial cohort. FD-PASS primary endpoint
was post-treatment aneurysm spatiotemporal mean velocity
reduction (AMVR) greater than 35%; which was shown in an
independent population to be an accurate surrogate for complete
aneurysm occlusion10. Predicted FD efficacy in the FD-PASS trial
was compared with the observations in three previously published
reference clinical trials (PUFS11, ASPIRe7 and PREMIER8) to
demonstrate whether an in-silico trial can replicate conventional
clinical trial findings in independent patient cohorts. The work-
flow and steps of the FD-PASS in-silico trial are illustrated in
Fig. 1.
Although not reported in PUFS, ASPIRe and PREMIER trials,
other studies found that a branch artery emerging from the
aneurysm sac12–14, fusiform aneurysm morphology12, bifurcation
aneurysm12, large/giant aneurysm size12,15 and age older than 70
years16,17 were among the risk factors associated with incomplete
aneurysm occlusion after flow diversion. The virtual FD-PASS
cohort was further stratified into different subgroups to explore
factors associated with FD device failure, including the presence
of a branch artery arising from the aneurysm and aneurysm sac
morphology. Moreover, FD-PASS generated useful evidence
beyond that gathered in conventional trials by enabling detailed
subgroup analyses to study other risk factors, such as hyperten-
sion. There is a growing consensus that assessment of post-flow
diversion thrombus composition must predict treatment success
in flow diverted aneurysms18–24. The FD-PASS in-silico trial
demonstrated utility of post-flow diversion thrombosis simula-
tions in individual virtual cases to further explore flow diversion
failure scenarios. Such secondary analyses or in-silico experi-
ments would not usually be feasible in a conventional clinical
trial, and could contribute to the improved design of medical
devices and reduction in adverse events in future.
Results
In-silico cohort characteristics. Eighty-two cases were retained
after applying the inclusion and exclusion criteria to the reference
@neurIST project population, which provided a sufficiently large
sample size according to the power calculations, as described in
the Methods section. Three-dimensional anatomic surface model
of this cohort was used to build the virtual patient cohort of FD-
PASS. Population statistics and measurements of the aneurysms
are provided in Table 1, along with a comparison of the in-silico
cohort vs. other trial cohorts from the literature. The FD-PASS
cohort matched the clinical trial cohorts well in terms of the age
and sex distribution, aneurysm location, mean aneurysm dome
and neck size. Hypertension was present approximately 50.0% of
the cases in the reference clinical trials (Table 1). To understand
how hypertension has affected the post-operative occlusion of
aneurysms, for each of the 82 virtual anatomies, we simulated two
physiological phenotypes, i.e., normotensive and hypertensive,
and presented the outcomes, separately, for each group.
The FD-PASS replicated the efficacy of flow diversion. The
reported success rates of total angiographic occlusion in the in-
silico and clinical trials are compared in Table 2. The FD-PASS
predicted occlusion rates were 82.9% and 67.1% for normotensive
and hypertensive patients, respectively, where an AMVR >35%
was considered successful occlusion. Considering the occlusion
rates reported by the reference trials within 6–12 months of
intervention, the predicted occlusion rate by the FD-PASS
replicated the previously reported values.
FD-PASS allowed subgroup analysis of PED failure scenarios.
Presence of a branch artery originating from the aneurysm sac,
large/giant aneurysm size and high aspect ratio (AR) were among
the most important risk factors associated with the flow diversion
failure12,25. The FD-PASS in-silico trial replicated the effect of
these morphological risk factors on aneurysm haemodynamics
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and occlusion (i.e., device failure). Aneurysm haemodynamics
was assessed before and after flow diversion by measuring the sac
space-and-time averaged velocity (STAV), neck maximum time-
averaged velocity (MTAV) and post-flow diversion reduction in
STAV (i.e., AMVR) and MTAV. The virtual FD-PASS cohort was
further stratified, and these haemodynamic variables were com-
pared between the subgroups of interest to explore the association
of the FD device failure with each of the risk factors, i.e., presence
of a branch artery, aneurysm size and AR (Fig. 2: first to third row
and Supplementary Tables 1–3).
PED failure in the presence of a branch artery. Among 82
virtual anatomies in the FD-PASS, 34 (41.5%) had branch arteries
originating from the aneurysm sac. Patient demographic and
aneurysm morphology characteristics did not significantly differ
between aneurysms with and those without a side branch
Fig. 1 Workflow of the FD-PASS in-silico trial. Virtual anatomies (N= 82) are selected from the retrospective cohort of the @neurIST study, following
clinical guidelines for flow diversion eligibility. Virtual PED flow diverters are implanted using the algorithm from38, followed by lumen mesh generation.
Carotid flow boundary conditions are generated using the model from54, representing patients with both normotensive and hypertensive conditions
(N= 164). The 3-D Navier–Stokes equations are solved and the results post-processed to measure the aneurysm mean velocity reduction (AMVR). A
threshold (AMVR >35%) is used to evaluate whether the aneurysm would have occluded completely.
Table 1 Population characteristics.
FD-PASS in-silico trial PUFS 29–31 ASPIRe7 PREMIER8
Number of aneurysms 82 109 207 141
Age, year
Mean ± SD (N) 54.6 ± 9.6 (82) 57.0 ± 11.3 (108) 59.9 ± 12.5 (191) 54.6 ± 11.3 (141)
Median 50.0 59.0 60.0
Range 36.0–85.0 30.2–75.0 25.0–89.0
Female sex, % (n/N) 78.0 (64/82) 88.9 (96/108) 83.8 (160/191) 87.9 (124/141)
Hypertension, % (n/N) – 55.6 (60/108) 53.9 (103/191) 51.1 (72/141)
Aneurysm size, mm
Mean ± SD (N) 9.1 ± 4.0 (82) 18.2 ± 6.5 (82) 14.5 ± 6.9 (207) 5.0 ± 1.9 (141)
Median 8.0 17.5 12.0 4.6
Range 3.5–25.5 6.2–36.1 0.9–41.0
Aneurysm neck, mm
Mean ± SD (N) 5.5 ± 1.4 (82) 8.8 ± 4.3 (108) 7.1 ± 4.2 (202) 4.0 ± 1.4 (141)
Median 5.0 8.1 6.0 3.7
Range 4.0–9.8 4.1–36.1 0.8–53.0
Aneurysm location
ICA/PCoA, % (n/N) 100 (82/82) 100 (108/108) 90.8 (188/207) 95 (134/141)
Multiple PEDs used, % (n/N) 0.0 (0/82) 98.1 (105/107) 18.8 (39/207) 6.4 (9/141)
Efficacy endpoint AMVR >35% as a proxy for angiographic
occlusion
Angiographic occlusion Angiographic occlusion Angiographic occlusion
ICA internal carotid artery, PCoA posterior communicating artery, PED pipeline embolisation device.
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(Table 3). No significant differences were observed in aneurysm
haemodynamics before flow diversion (Supplementary Table 1).
However, the post-treatment reductions in both STAV and
MTAV were significantly higher in aneurysms without a side
branch (p= 0.009 and 0.002, respectively; Fig. 2: first row; Sup-
plementary Table 1). Occlusion rates, determined by AMVR,
were 70.6% and 91.7% for normotensive aneurysms with and
without side branches, respectively (p < 0.05; Table 4). These
reduced to 52.9% and 77.1% for hypertensive aneurysms with and
without side branches, respectively (p < 0.05; Table 4). The virtual
flow simulation indicates that a side branch is likely to cause
higher residual flow within the aneurysm sac.
PED failure in large/giant and high aspect ratio aneurysms.
Among 82 virtual patients in the FD-PASS cohort, 26 (31.7%)
patients had large/giant aneurysms (diameter >10 mm). The
demographic characteristics did not significantly differ between
the large/giant and small aneurysm subgroups (Table 5). While
the pre-treatment aneurysm STAV was significantly higher in the
small aneurysm subgroup (p < 0.001), the post-treatment reduc-
tion in the sac STAV (AMVR) did not significantly differ between
the two subgroups (Fig. 2: second row; Supplementary Table 2).
Occlusion rates, determined by AMVR, were 73.1% and 87.5% for
normotensive large/giant and small aneurysms, respectively
(Table 4, p ≈ 0.1). These reduced to 50.0% and 75.0% for
hypertensive large/giant and small aneurysms, respectively, (p <
0.05; Table 4).
Among 82 virtual patients in the FD-PASS cohort, 18 (21.9%)
patients had aneurysms with an AR greater than 1.6. The
demographic characteristics did not significantly differ between
the subgroups with high and low AR aneurysms (Table 5).
However, the aneurysms were significantly larger in the high AR
subgroup (p < 0.001), and the pre-treatment aneurysm STAV was
significantly higher in the low AR aneurysm (AR < 1.6) subgroup
(p < 0.001). Even so, the post-treatment reduction in the sac
STAV (AMVR) or MTAV did not significantly differ between the
two subgroups (Fig. 2: third row; Supplementary Table 3).
Occlusion rates with respect to the AMVR were 77.8% and 84.4%
for the normotensive high and low AR aneurysms, respectively
(Table 4). These reduced to 55.6% and 70.3% for hypertensive
high and low AR aneurysms, respectively (Table 4). These
differences were not statistically significant (p > 0.05). Taken
together, from a purely haemodynamic viewpoint, large/giant
aneurysms or aneurysms with high ARs did not respond
differently to flow diversion compared to small aneurysms or
aneurysms with lower ARs, respectively.
FD-PASS expanded exploratory analyses of clinical trials. One
benefit of in-silico trials is the practicality to perform exploratory
experiments to provide new insights and generate new hypoth-
eses. PED flow diversion efficacy in the presence of hypertension
has been clinically less studied so far. The in-silico nature of FD-
PASS allowed us to perform normotensive and hypertensive
simulations for each of the 82 virtual anatomies. We computa-
tionally estimated reductions in STAV (i.e., AMVR) and MTAV
after flow diversion and compared them between the normo-
tensive and hypertensive subgroups (Fig. 2: fourth row and
Supplementary Table 4). No significant differences were observed
in aneurysm haemodynamics before flow diversion (Supple-
mentary Table 4). However, the post-treatment reductions in
both STAV and MTAV were significantly higher in normotensive
patients (p < 0.001 and p= 0.007, respectively; Fig. 2: fourth row;
Supplementary Table 4). Occlusion rates, determined by AMVR,
were 82.9% and 67.1% for normotensive and hypertensive
patients, respectively (p < 0.05; Table 4). Our simulation results
clearly show that hypertension is likely to cause less effective flow
diversion. We argue that this observation demonstrates how the
FD-PASS can expand insights from conventional clinical trials
and be used to generate hypotheses or priors that can augment
later clinical trials.
Although none of the three reference clinical trials reported a
significant association between aneurysm morphology and
occlusion rates, several other clinical studies have reported cases
of haemorrhagic stroke due to the delayed rupture of complex-
shaped aneurysms after flow diversion15,20. In addition, the
IntrePED study reported an association between hypertension
and ischaemic stroke in flow-diverted aneurysms26. While the
ability to investigate such scenarios is limited in real patient
cohorts, the in-silico nature of FD-PASS allows us to apply
advanced modelling techniques to allow the generation and
examination of clinical hypotheses about these observed compli-
cations. To achieve this aim, we simulated post-flow diversion
clot formation in our virtual patients with ICA aneurysms.
The clot formation model and its validation are detailed in27, and
all the model parameters used were the same for all virtual
patients. The clot formation model was simulated until a stable
steady-state was reached, after which the stability of the virtual
Table 2 Flow diversion efficacy: angiographic flow reduction in the in-silico trial compared to measures of flow diversion efficacy
in three reference clinical trials.
FD-PASS in-silico trial PUFS29–31 ASPIRe7 PREMIER8
Number of aneurysms 82 (NT) 82 (HT) 109 207 141
FD device PED PED PED PED
Flow diversion efficacy 82.9% (NT) 67.1% (HT) 73.6% (at 6 months) 86.8% (at 1 year) 95.2%
(at 5 years)
74.8% (at 7.8 months) 76.8% (at 1 year)
FD flow diverter, NT normotensive patients, HT hypertensive patients, PED pipeline embolisation device.
Table 3 Demographics and morphological characteristics of
aneurysms with/without a side branch.
With side branch Without side branch p value
Number of aneurysms 34 48
Age, year
Mean ± SD 55.0 ± 9.4 54.4 ± 9.9 0.78
Median 51.0 50.0
Range 36.0–77.0 36.0–85.0
Female sex, % (n/N) 82.3 (28/34) 75.0 (36/48) 0.43
Aneurysm size, mm








Mean ± SD 0.17 ± 0.06 0.15 ± 0.08 0.27
Median 0.17 0.16
Range 0.05–0.30 0.03–0.35
p values were computed using two-tailed t-tests.
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clot was evaluated using the flow-induced platelet index (FiPi).
Compared with experimental results, FiPi values <0.15 were
considered indicative of unstable red thrombi27, which have been
linked to post-operative aneurysm rupture even in the presence of
complete occlusion20. Predictions were insensitive to changes in
this threshold of up to 30%. Therefore, we used FiPi <0.15 as a
data-independent threshold to identify red thrombi in the FD-
PASS data.
Fig. 2 Haemodynamic performance of flow diversion in FD-PASS. Comparison of haemodynamic performance of the PED in aneurysms with and without
a branch artery emerging from the sac (first row), aneurysms with a diameter <10mm (small) and >10mm (large/giant aneurysms) (second row),
aneurysms with a high and low AR (third row) and hypertensive and normotensive aneurysms (fourth row). Left column: post-flow diversion reduction in
the space-and-time-averaged velocity (STAV) in the aneurysm sac. Right column: post-flow diversion reduction in the maximum time-averaged velocity
(MTAV) entering the aneurysm at the neck. The results are shown for normotensive patients (N= 82), and hypertensive patients (N= 82). STAV space-
and-time-averaged velocity, MTAV maximum time-averaged velocity, AR aspect ratio. The central mark denotes the mean, the smaller box denotes 1.96
standard error of the mean (SEM) and the larger box denotes the standard deviation (SD). p values were computed from one-tailed t-tests (unpaired).
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Haemorrhagic stroke in large complex-shaped aneurysms. We
simulated post-treatment clotting in two virtual patients: one with
a typical simple aneurysm (Fig. 3, case 1, size = 6.1 mm, AR =
0.72, non-sphericity = 0.08) and one with a complex-shaped large
aneurysm (Fig. 3, case 2, size = 16.7 mm, AR = 1.9, non-
sphericity = 0.25). Both aneurysms clotted within a similar time
scale. The clot that formed in the simple aneurysm (case 1) was
an organised white thrombus with high platelet content
throughout the formation and grew in a layer-wise manner. In
the more complex case 2, we observed the rapid formation of a
non-organised red thrombus (FiPi < 0.15) inside the aneurysm
bleb. A persistent flow jet was present in the sac during the entire
time course of the clot formation. It has been hypothesised that
the co-presence of unorganised red thrombi and a persisting flow
jet in complex-shaped flow-diverted aneurysms can cause the
delayed rupture of aneurysms and haemorrhagic stroke20.
The IntrePED study also reported an association between large
aneurysm size and haemorrhagic stroke after flow diversion15.
Our observations demonstrate how the FD-PASS can test
experimental scenarios to explore why FDs fail in complex-
shaped aneurysms.
Ischaemic stroke in hypertensive patients. Next, we simulated
post-treatment clotting in two virtual patients with precisely the
same aneurysm morphology (Fig. 3, cases 3 and 4, size = 7.2 mm,
AR = 1.25, non-sphericity = 0.21), but differing blood pressure
levels (one normotensive and the other hypertensive). We
observed the rapid formation of non-organised thrombi in
the aneurysm bleb. However, in the normotensive case (case 3),
the course of clot formation continued with the growth of an
organised white thrombus that filled the aneurysm sac, keeping
the ophthalmic artery patent. The entire course of thrombosis was
almost ten-times faster than that in cases 1 and 2, so this
aneurysm may occlude fast enough and the presence of a red
thrombus in the bleb would not result in aneurysm rupture, as the
organised thrombus filled the aneurysm and prevented blood flow
into the sac. In hypertensive case 4, which was hypertensive,
however, we observed patency of the aneurysm core and the
transport/formation of a red thrombus in the branching posterior
communicating artery (PCoA), which could cause a stroke in the
downstream vessel. Ischaemic stroke has been reported in
hypertensive patients treated with FDs26. We argue that these
observations provide another demonstration of how the FD-PASS
can be used for virtual experimentation to explain concepts that
are difficult to study in conventional clinical trials, such as why
ischaemia occurs in such patients.
Discussion
Viceconti et al.28 defined three principles that every in-silico trial
should follow to be credibly comparable to a conventional clinical
Table 4 Subgroup analysis: the effects of the presence of a side branch, aneurysm size, aspect ratio and hypertension on flow
diversion efficacy (determined by AMVR).
Normotensive Hypertensive
SO/subtotal Difference (95% CI) p value SO/subtotal Difference (95% CI) p value
Side branch
Yes 70.6% (24/34) 21.1% (4.2 to 38.6%) 0.013 52.9% (18/34) 24.2% (3.4 to 43.0%) 0.023
No 91.7% (44/48) Ref Ref 77.1% (37/48) Ref Ref
Size
>10mm 73.1% (19/26) 14.4% (−2.8 to 34.6%) 0.108 50.0% (13/26) 25.0% (3.0 to 45.3%) 0.026
<10mm 87.5% (49/56) Ref Ref 75.0% (42/56) Ref Ref
Aspect ratio
>1.6 77.8% (14/18) 6.7% (−10.5 to 30.6%) 0.514 55.6% (10/18) 14.7% (−8.5 to 38.7%) 0.242
<1.6 84.4% (54/64) Ref Ref 70.3% (45/64) Ref Ref
Hypertension 82.9% (68/82) Ref Ref 67.1% (55/82) 15.8% (2.6 to 28.4%) 0.0196
p values were computed using the χ2 test.
AMVR aneurysm mean (time-averaged) velocity reduction, SO successful occlusion indicated by AMVR, Ref group taken as reference.
Table 5 Demographics and morphological characteristics of small/large and high/low aspect ratio aneurysms.
Size >10 mm Size <10mm p value AR >1.6 AR <1.6 p value
Number of aneurysms 52 112 36 128
Age, year
Mean ± SD 52.1 ± 9.2 55.8 ± 9.7 0.10 51.2 ± 7.9 55.6 ± 9.9 0.10
Median 50.0 52.0 50.0 50.0
Range 36.0–77.0 36.0–85.0 40.0–74.0 36.0–85.0
Female sex, % (n/N) 73.1 (38/52) 80.36 (90/112) 0.46 83.4 (30/36) 76.6 (98/128) 0.55
Aneurysm size, mm
Mean ± SD 13.6 ± 3.9 6.9 ± 1.6 4.0e–34 14.2 ± 4.5 7.6 ± 2.3 2.7e–24
Median 11.8 7.0 12.9 7.2
Range 10.1–25.5 3.5–9.9 9.7–25.5 3.5–15.2
Aneurysm neck, mm
Mean ± SD 6.7 ± 1.6 4.9 ± 0.8 3.0e–17 5.8 ± 1.4 5.4 ± 1.4 0.064
Median 6.6 4.7 5.6 5.0
Range 4.3–9.8 4.0–7.5 4.1–8.4 4.0–9.8
Non-sphericity
Mean ± SD 0.20 ± 0.06 0.14 ± 0.07 4.1e–6 0.24 ± .04 0.14 ± 0.06 3.8e–15
Median 0.21 0.15 0.23 0.14
Range 0.06–0.35 0.03–0.30 0.16–0.35 0.03–0.29
p values were computed using the two-tailed t-test.
SB side branch, STAV space-and-time-averaged velocity, MTAV maximum time-averaged velocity.
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trial: (i) every virtual patient has to be plausible when compared
to patients in a clinical trial cohort, (ii) the accuracy of the virtual
endpoint should represent the accuracy of the endpoint in the
clinical trial cohort and (iii) for sufficiently large physical and
virtual cohorts, the conclusions made from observed effects
should be identical. The FD-PASS in-silico trial satisfied these
three principles in the following ways.
(i) The virtual patients were simulated from real, patient-
specific imaging data, and virtual patient selection was performed
following the same inclusion/exclusion criteria as the reference
clinical trials. This allowed the direct comparison between the
demographic and anatomical characteristics of virtual and real
patient cohorts. All virtual patient anatomies in the FD-PASS
were built based on the @neurIST 3D rotational angiography
imaging cohort with appropriate inclusion/exclusion criteria
applied to select the virtual cohort. Therefore, the virtual patients
simulated here were entirely independent of the actual patients in
the reference clinical trials.
(ii) Validated computational models were used, and we
ensured that the endpoints of the in-silico trial followed a similar
distribution as the clinical endpoints. The computational in-silico
trial setup of the FD-PASS trial was an orchestration of building
Fig. 3 Time course of post-treatment clot formation in four virtual patients. The flow-induced platelet index (FiPi) is a measure of the clot platelet
content and indicates whether the clot is a red thrombus (FiPi < 0.15) or white thrombus (FiPi > 0.15). White thrombi have higher stability than red thrombi.
Red thrombi are also known to induce autolytic activities in the wall, resulting in the weakening of the wall and aneurysm rupture. Time values are shown in
units of simulation time and are not representative of physiological time scales but are reported to enable comparisons between patients.
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blocks that were presumed to be adequately validated in previous
studies (see Methods). What distinguishes the concept of vali-
dation of this in-silico trial from that in personalised medicine or
patient-specific modelling paradigms is that, here, the underlying
models and simulations were not tailored for a specific patient but
should be able to represent medical device performance over an
entire population of virtual patients.
(iii) We demonstrated that similar quantitative conclusions can
be made about the performance of FDs in both in-silico trials and
clinical trials. This was achieved in the FD-PASS by showing that
the predicted post-operative occlusion likelihood were similar to
results observed in the reference clinical trials.
Three major clinical trials on PED FDs, i.e., PUFS, ASPIRe and
PREMIER, reported angiographic occlusion rates of 74–77% at
approximately 1 year after flow diversion7,8,29–31. Large meta-
analyses of flow diversion efficacy confirmed similar occlusion
rates within 6–12 months after treatment7. Longer-term occlu-
sion, however, increased up to 95%, as reported at 5 years in the
PUFS31. Given the ideal conditions of trials such as PUFS, in16, it
was argued that the overall long-term occlusion rate after PED
treatment could reach 85%. The FD-PASS in-silico trial estimated
an occlusion rate of 82.9% in patients with normal blood pressure
and 67% in hypertensive patients, which replicated the occlusion
rates reported in the reference clinical trials. FD-PASS estimation
of occlusion rate was performed based on one primary endpoint,
the post-treatment AMVR >35% as a surrogate for angiographic
occlusion, which was obtained by computational simulation of an
independent cohort of N= 12 flow diverted aneurysms10. While
we emphasise that FD-PASS did not aim to devise or validate a
predictive surrogate endpoint, we explored what happens to the
occlusion rates when we set a different surrogate endpoint. We
examined AMVR >20% and post-treatment inflow reduction
(INFR) at the aneurysm neck >30%, which were presented as
accurate simulation-based predictors of flow diversion success in
a cohort of 36 patients treated with intrasaccular FDs32. Occlu-
sion rates of 78% and 83% were achieved when we used AMVR
>20% and INFR >30% as primary endpoints, respectively. This
demonstrated that the estimated occlusion rates were not sensi-
tive to the choice of surrogate endpoint.
Although not reported in PUFS, ASPIRe and PREMIER trials,
other studies listed a branch artery emerging from the aneurysm
sac12–14, large/giant aneurysm size12,15 among the risk factors
associated with incomplete aneurysm occlusion after flow diver-
sion. In-silico trials can offer detailed subgroup analysis of the
outcomes. On univariate analysis of results presented in4, FD-
PASS showed higher risks of incomplete occlusion in aneurysms
with a branch vessel (risk ratio (RR): 3.53; CI: 1.21–10.32;
p= 0.021) but not in aneurysms with size >10 mm (RR: 2.15; CI:
0.84–5.51; p= 0.109) (Table 6).
The association of hypertension with incomplete aneurysm
occlusion was also not reported in the comparative human trials,
presumably due to the impracticality of recruiting a balanced
cohort of patients to allow an efficient assessment of device
performance under different physiological conditions. The FD-
PASS trial allowed the comparison of hyper- vs. normotensive
patients, which is challenging to investigate with human partici-
pants, thus generating useful evidence beyond that gathered in
conventional trials. For each virtual patient, in whom we were
able to maintain the anatomy and the deployed device config-
uration, we studied the post-treatment haemodynamics with two
different physiological flow conditions (normotensive and
hypertensive). On Univariate analysis, we observed higher risks of
incomplete occlusion in hypertensive patients (RR: 1.93; CI:
1.09–3.40; p= 0.023) (Table 6). Such control of sources of
variability are not readily available in conventional clinical trials.
The IntrePED registry15,26,33 found higher risks of ischaemic
and haemorrhagic stroke in hypertensive patients and in patients
with large/giant aneurysms, respectively. To date, clinical trials
have been limited in their ability to identify the underlying
mechanisms relating to the increased stroke risk. For instance,
based on observations in three flow-diverted aneurysms, Kulcsár
et al.20 hypothesised that the co-presence of non-organised red
thrombi and a persistent flow jet could be associated with post-
treatment rupture in large and complex-shaped aneurysms. The
likelihood of such complications cannot be assessed merely based
on haemodynamic simulations. In our small-scale secondary
analysis of the FD-PASS cohort, thrombosis formation was
simulated in four patients treated with a PED: one with a small
aneurysm, one with a large complex-shaped aneurysm, and two
with the same anatomy but different flow conditions (hyperten-
sive and normotensive). We observed deposition of the clot into
the PCoA in the hypertensive patient, which may explain the
ischaemic stroke event in this patient. We also observed the co-
presence of an entering jet and non-organised red thrombi in the
complex-shaped aneurysm, which may explain the elevated risk
of post-treatment rupture as reported in20. This provides a
demonstration of how the in-silico trials can utilise advanced
modelling and simulation techniques for virtual experimentation
of scenarios that are impossible to study in conventional clinical
trials, such as investigation of clot composition and stability after
flow diversion.
The findings from the FD-PASS in-silico trial replicated those
of previously published conventional clinical trials. This study
enabled further stratification of the virtual patient cohort to assess
efficacy in different subgroups. We argue that although large-
scale studies are required for the general acceptance of medical
devices and the overall evaluation of associated risks, as recom-
mended in17,34, treatment planning for devices with complex
mechanisms of action (such as the PED) needs to be determined
individually for each patient. The FD-PASS trial offered addi-
tional information about populations more likely to experience
device failure that would not usually be available from a con-
ventional clinical trial. We demonstrated the use of advanced
modelling and simulation techniques to explain the underlying
mechanisms of complications and to advise clinical decisions on a
case-by-case basis. Moreover, while issues related to device sizing,
Table 6 Subgroup analysis: RRs of incomplete occlusion associated with the presence of a side branch, aneurysm size, aspect
ratio and hypertension.
Normotensive Hypertensive
Relative risk (95% CI) p value Relative risk (95% CI) p value Relative risk (95% CI) p value
Side branch presence 3.53 (1.21–10.32) 0.021 2.05 (1.09–3.85) 0.025
Size (>10 mm) 2.15 (0.84–5.51) 0.109 2.00 (1.10–3.62) 0.022
Aspect ratio (>1.6) 1.42 (0.50–4.00) 0.504 1.49 (0.79–2.83) 0.216
Hypertension 1.93 (1.09–3.40) 0.023
p values were computed using the two-tailed t-test.
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positioning, deployment and apposition with the vessel wall were
not considered in the FD-PASS trial, the in-silico clinical trial
approach does also offer benefits in this respect because multiple
device deployments can be performed on the same patient to
compare different deployment strategies. Were a more detailed
deployment model implemented, the FD-PASS trial could also be
extended to perform such comparisons. Future work will involve
setting up a prospective digital twin study, where patients treated
with the PED are followed, and aneurysm occlusion and
thrombus formation are monitored by angiographic imaging
after 12 months. Such a study would allow more comprehensive
in-vivo validation of the predictions of our thrombus
formation model.
Methods
FD-PASS in-silico trial design. A population of 301 patient-specific simulation-
ready surface models of saccular intracranial aneurysms from the @neurIST
project9 was the reference population in this study. The mean age of the population
was 51.2 ± 8.2 years, and 81.2% were female. The mean aneurysm size was 7.4 ±
3.9 mm (range 2.0–31.0). The mean aneurysm neck size was 4.6 ± 1.7 mm (range
1.7–12.2). Aneurysms, if treated, were coiled, and treatment outcomes were not
available for this population. However, as the primary aim of the FD-PASS trial
was to perform an in-silico replication of outcomes from three previously pub-
lished flow diversion clinical trials in an independent population, a direct com-
parison of the treatment outcomes between the real @neurIST project cases and
their digital twins was not of interest. Therefore, we used the 301 untreated
aneurysms as our reference population.
Inclusion criteria and virtual patient selection. The inclusion criteria in this
study were as follows: wide-neck (≥4 mm), unruptured aneurysm arising from the
ICA (cavernous through the anterior choroidal segments). These criteria based on
conventional clinical trials such as PUFS30 and PREMIER8. Aneurysm dimensions
were measured on the virtual anatomies obtained from 3D rotational angiography
images. The primary cause of exclusion was poor image resolution that prevented
the creation of virtual anatomy models amenable to computational simulations.
Eighty-two cases were retained after applying the inclusion and exclusion criteria to
the reference cohort, which provided a sufficiently large sample size according to
the power calculations, as described in the next section.
For each of the 82 virtual anatomies, we simulated two physiological
phenotypes, i.e., normotensive and hypertensive. To do this, we used a statistical
model for cerebral flow variability (see35 for model details) to generate both
normotensive and hypertensive flow waveforms and then used these waveforms as
flow boundary conditions in blood flow simulations for each virtual patient. The
total size of the virtual cohort was then 2 × 82= 164 virtual patients with 82
distinct anatomies, each with two systemic flow phenotypes. Since hypertension
was present in approximately 50% of the cases in the reference clinical trials
(Table 1), this 50/50 distribution in the FD-PASS allowed meaningful subgroup
analyses to understand how hypertension affected the post-operative occlusion of
aneurysms.
Virtual cohort size and power calculation. When designing in-silico trials, the
sample size and variability (e.g., in anatomies) of the underlying patient cohort
should be such that it reflects real life. The sample size should be large enough to
enable to detect relevant effects of the order of magnitude expected in conventional
clinical trials. Regarding in-silico patient variability, the source cohort character-
istics must be evaluated against the corresponding distributions from real trials.
The FD-PASS in-silico trial was a single-arm study. Its primary endpoint was
AMVR >35% as a surrogate for complete occlusion of the aneurysm after flow
diversion. Based on data available in the literature, we formulated these hypotheses:
85% of patients with wide-necked aneurysms will have complete occlusion in the
group treated using the FD; 70% of patients with wide-necked aneurysms will have
complete occlusion in the group treated using the conventional techniques (e.g.,
coiling, surgical clipping, etc.)36,37. Considering a type I error of 0.05 and a power
of 90%, the number of subjects required to demonstrate a significant difference of
15% between the study group (flow diversion) and the literature-based efficacy of
the conventional techniques was 82 patients. Considering a discard rate of 10%, a
total of 90 virtual patients should be included.
Flow-diverter virtual device model. In the FD-PASS trial, digital models of PEDs,
consisting of 48 wires with a 30-micrometre thickness were created and deployed
in the parent vessel using a fast virtual stent (FVS) placement method. The FVS
method was validated based on in-vitro experiments in38. We followed the
guidelines presented in39,40 to select the PED. Hence, the fully-expanded device
diameter was equal to that of the proximal parent vessel and the maximal device
expansion at the neck was ensured. We focused on the flow diversion efficacy of the
PED stent and techniques used to improve the local stent porosity, e.g., the push-
pull technique41, or wall apposition were not considered. A porosity of 70% at the
neck is reported to be optimal for aneurysm occlusion42,43. This is not achievable in
practice due to oversizing, device deformation, manipulation or aneurysm
location40,42. Multi-device constructs can achieve the favourable porosity, although
it increases the risk of ischaemic complications39,42,44. A retrospective study of 523
PED treatments proved the aneurysm neck metal coverage necessary for the suc-
cessful occlusion of aneurysms17. However, in this study, no significant association
was found between the number of devices per patient and the aneurysm occlusion
rate. In another retrospective study of 178 PED treatments, Chalouhi et al.45 found
similar occlusion rates but more complications in aneurysms treated with multiple
devices compared to those treated with a single device. Zhang et al.46 used com-
putational simulations and showed that a porosity of around 70% is sufficient to
induce haemodynamic stasis required for sac thrombosis. Accordingly, we remark
that, considering haemodynamic performance of FDs, number of PEDs used is of
less relevance if an adequate neck metal coverage is achieved. In FD-PASS, all
virtual patients were treated with a single device. However, we controlled the
aneurysm neck coverage and ensured good stent porosity that was comparable to
that in clinical practice. The mean porosity at the neck averaged over the virtual
population was 73.2% ± 3.8% with minimum and maximum mean porosities of
66.6% and 82.6%, respectively. The virtual PED porosity values were in accordance
with those reported in clinical studies (e.g.,42) and other computational studies
(e.g.,38). Since we were only interested in the effect of FDs on the intra-aneurysmal
flow, the FD models were clipped to reduce the computational costs. Maintaining
portions covering the aneurysm neck, portions of the FDs laying entirely on the
vessel wall were removed. The effect of partial stent modelling on intra-aneurysmal
haemodynamics was found to be negligible in a previous study47.
Virtual patient anatomies. Retrospective patient-specific imaging data from the
@neurIST project (Integrated Biomedical Informatics for the Management of
Cerebral Aneurysms;9) were used to create the FD-PASS virtual patient cohort. The
@neurIST project was a 4-year project initiated in 2006 that comprised 28 public
and private institutions from 12 European countries. Within the project, clinical and
imaging data were collected from nearly 500 patients with ruptured and unruptured
aneurysms. As part of the @neurIST processing toolchain, anatomic surface models
were obtained for over 300 aneurysms from 3D rotational angiography images using
an automatic segmentation method based on geodesic active regions. Details of the
processing toolchain and the verification and validation of the techniques used to
generate the @neurIST cohort of virtual anatomies are reported in48,49. A popula-
tion of 301 patient-specific simulation-ready surface models of saccular intracranial
aneurysms from the @neurIST project was the reference population in this study. In
FD-PASS, aneurysm dimensions were measured on the virtual anatomies obtained
from 3D rotational angiography images.
For each virtual anatomy, the inlet branches were truncated at the beginning of
the ICA cavernous segment and extruded by an entry length of 5× the inlet
diameter to allow for fully developed flow. Outlet branches were automatically
clipped 20 mm after their proximal bifurcation. Branches shorter than 20 mm were
extruded before truncation. Volumetric meshes were generated using ANSYS
ICEM CFD v19.1 (Ansys Inc., Canonsburg, PA, USA). Tetrahedral elements with a
maximum edge size of 0.2 mm and five layers of prismatic elements with a
maximum edge size of 0.1 mm were used to discretise the core region of the
computational domain. Where the PED was present, a maximum edge size of
0.01 mm was set on the wires.
Virtual physiology flow conditions. The processed virtual anatomies were then
combined with the virtual physiology to generate virtual patients, who were treated
with virtual devices and used for blood flow or thrombosis simulations. Unsteady
blood flow simulations were solved in ANSYS CFX v19.1 (Ansys Inc., Canonsburg,
PA, USA) using a finite volume method. Arterial wall distensibility was not con-
sidered (rigid-wall assumption). Time-varying inflow boundary conditions were
imposed based on the normotensive and hypertensive waveforms generated for each
virtual anatomy (details are provided below). A Poiseuille profile was enforced onto
the cross-sectionally averaged flow rate given by the patient-specific inlet conditions.
In blood flow simulations with no thrombosis simulation, blood was considered
incompressible and Newtonian with a density of 1066 kg ⋅m−3 and dynamic viscosity
of 0.0035 Pa ⋅ s. The cardiac cycle was discretised in time into 200 equal steps. The
time-step size was set according to the @neurIST processing toolchain; time-step size
independence tests were performed, as described in49,50. The validity of the above
techniques and assumptions was studied in50–52 and more overviewed in53. Simu-
lations were run for three cardiac cycles and results from the last cycle were used in
the analyses, to reduce the effects of initial transients. Mesh independence tests were
performed for both blood flow and thrombosis simulations and reported in27.
For each virtual anatomy in the FD-PASS cohort, we simulated two
physiological flow conditions, i.e., a normotensive condition and a hypertensive
condition, using models of cerebral autoregulation and by imposing two different
inflow boundary waveforms at the ICA inlet boundary. Normotensive ICA flow
waveforms were taken as the mean of a virtual population of waveforms generated
by a Gaussian process model (GPM) trained on patient-specific phase-contrast
magnetic resonance imaging measurements of ICA flow in 17 healthy young adults
(age = 28 ± 7 years). Details on this GPM and its validation are reported in35,54. To
maintain a physiologically realistic flow specific to each virtual patient, Poiseuille’s
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law was used to scale the GPM-generated waveforms such that the time-averaged
wall shear stress was the physiological value of 1.5 Pa at the ICA inlet. While the
definition of hypertension has often focused on the elevation of diastolic blood
pressure, it has been shown that systolic blood pressure (SPB ≥140 mmHg) is
superior when defining hypertension and the associated cardiovascular risks55. To
generate hypertensive flow waveforms, we used a model of intra-subject flow
variability that incorporated a mathematical description of the cerebral
autoregulation system. The model took the normotensive flow waveform calculated
for each virtual anatomy, estimated its associated normotensive pressure waveform,
scaled the pressure waveform to a hypertensive pressure waveform (SPB
≥140 mmHg) and finally calculated the associated hypertensive flow waveform.
The mean age of the virtual population used in FD-PASS trial was 54.6 ± 9.62 years.
However, the mean age of the population we used for modelling normotensive flow
conditions was 28 ± 7. When producing hypertensive flow conditions for each
virtual anatomy, the dependency on age was modelled using the methods detailed
in54. However, the effect of age on flow diversion outcomes has previously been
hypothesised to be related to inadequate endothelialisation in elderly
individuals16,17, which was beyond the scope of the FD-PASS trial. Therefore, we
argue that age differences between the anatomical and normotensive physiological
populations had a minimal effect on the FD-PASS findings.
Virtual thrombus formation. A thrombus formation model was applied in a
subset of virtual patients to better understand the possible causes of device failure.
This model was used to distinguish between two types of thrombi that can form
inside the aneurysm post-treatment: white thrombi, which are rich in fibrin and
platelets, and red thrombi. Red thrombi are characterised by (i) fewer enmeshed
platelets, (ii) not facilitating the formation of a neointimal layer, (iii) being prone to
continuous fibrinolysis and renewal and (iv) inducing autolytic activities in the wall
resulting in the weakening of the wall and ultimately rupture. Non-organised red
thrombi after flow diversion have been suggested as a potential predictor for post-
treatment rupture56. We previously developed and validated a coupled flow and
thrombosis model27 capable of predicting the type of thrombus and the resulting
stability of the clot that forms after flow diversion. The bulk initiation and pro-
pagation mechanisms for thrombosis were assumed to be due to flow stasis only,
and initiation due to vessel wall injury or high platelet shear was not modelled.
After placing a FD, thrombosis was assumed to initiate in regions with a time-
averaged shear rate (SR) below SRt= 25s−157 and residence time (RT) greater than
RTt= 5s58. The model included five biochemical species: prothrombin, thrombin,
anti-thrombin, fibrinogen, fibrin, and three categories of platelets (resting platelets,
activated platelets and fibrin bound aggregated platelets). Four biochemically
coupled events were modelled to simulate the formation of a clot consisting of a
fibrin mesh and aggregated platelets. (i) Thrombin generation occurred by the
conversion of prothrombin to thrombin on the surface of resting and activated
platelets, where the reaction kinetics were faster for activated platelets. Thrombin
inhibition by its primary plasma inhibitor (anti-thrombin) in the absence of
heparin catalysis was also considered. (ii) Fibrin generation occurred in the pre-
sence of thrombin, which converted fibrinogen to fibrin monomers. We did not
consider further polymerisation of the fibrin monomers. (iii) Platelet activation
occurred when resting platelets became activated by exposure to thrombin or other
activated platelets. The latter mechanism was a surrogate for activation by agonists
released from other activated platelets59. (iv) Platelet aggregation in the presence of
fibrin occurred when platelets attached to the fibrin network aggregated to form
bound platelets. Bound platelets were assumed to activate prothrombin and other
resting platelets. The governing equations for the coupled system of blood flow and
post-flow diversion thrombosis were reported in27, in which the model was vali-
dated with in-vitro experiments. The momentum and transport equations for
biochemical species were solved in ANSYS CFX v19.1 (Ansys Inc., Canonsburg,
PA, USA) using a finite volume method. Simulations of the coupled flow and
thrombosis were run for 400 s of simulation time using CFX’s adaptive time-
stepping with the minimum, maximum, and initial time-steps of 0.0001, 0.05 and
0.01 s. Solutions at each time step converged when the maximum residual of the
computational domain was less than 5 × 10−4.
To quantitatively measure the stability of the intra-aneurysmal thrombus, we
defined the FiPi as the relative difference of the platelet concentration between a








In Eq. (1), Crp,0 and Cap,0 are the initial concentrations of resting and activated
platelets in clot-free blood, respectively. FiPi quantified the effect of blood flow on
the transport of platelets to and from the site of clot formation and on the final
platelet content of the formed clot.
Definition of the primary endpoint. Clinical trials evaluating devices for the
treatment of aneurysm typically use endpoints such as neurological morbidity and
mortality, intracranial haemorrhage and ischaemic stroke as measures of safety; a
typical efficacy endpoints is the angiographic occlusion rate measured using the
Raymond-Roy 5-point occlusion scale at 180 days and 1 year. Since a major
purpose of in-silico trials is to help improve the design of an investigational device
before it goes to clinical safety trials in humans, the FD-PASS focused solely on
device efficacy as the primary endpoint.
While angiographic occlusion immediately post-intervention can be simulated
in the computational model, the simulation of long-term post-operative outcomes
(e.g., at 1 year) is not feasible due to the limited understanding of the long-term
physiological response. Several groups have performed computational fluid
dynamics studies of cerebral aneurysms10,60,61 and suggested the use post-flow
diversion aneurysm mean velocity as a proxy haemodynamic metric for predicting
aneurysm occlusion. In10, it was demonstrated in 12 patients who had a reduction
of over 35% in the aneurysm mean velocity resulted in aneurysm occlusion with
99% sensitivity. Therefore, we focused on one primary endpoint, the post-
treatment AMVR, as a surrogate for angiographic occlusion and set an AMVR
>35% as the data-independent criterion for flow diversion success.
Reference human clinical trials. The PUFS29–31 was a prospective multi-centre,
single-arm, trial conducted between 2008 and 2014. Patients were included if they
had a large/giant ICA aneurysm (petrous through superior hypophyseal segments)
larger than 10 mm in diameter and with a neck larger than 4 mm. A total of 108
patients with 108 aneurysms were enrolled and treated with PED in ten centres.
The efficacy endpoint of the study was complete angiographic occlusion of the
aneurysm without major (>50%) stenosis of the parent artery after 180 days and 1,
3, and 5 years. Occlusion rates were approximately 75–95% at 6 months to 5 years.
The ASPIRe7 was a prospective single-arm, multi-centre observational study. It
evaluated all patients who consented and were treated with PED over 3 years in 28
centres. A total of 191 patients with 207 aneurysms were enrolled. The efficacy
endpoint of the study was complete angiographic occlusion of the aneurysm at the
final follow-up. Occlusion rates were approximately 75% with a median follow-up
time of 7.8 months.
The PREMIER8 was a prospective single-arm, multi-centre trial conducted
between 2014 and 2016. Patients were included if they had a small-/medium-sized
ICA or vertebral artery aneurysm measuring ≤12mm in diameter, with neck ≥4mm
or a dome to neck ratio ≤1.5. A total of 141 patients with 141 aneurysms were
enrolled and treated with PED in 23 centres. The efficacy endpoint of the study was
complete angiographic occlusion of the aneurysm without major (>50%) stenosis of
the parent artery after 1 year. Occlusion rates were approximately 77% at 1 year.
Statistical analysis. Continuous variables are presented as the number of obser-
vations and the mean and standard deviation or the median, minimum and
maximum values. We used an unpaired Student’s t-test to compare continuous
variables. Categorical variables are presented using frequency distributions and
cross-tabulations. We used contingency table analyses (χ2 tests) to compare cate-
gorical variables. To evaluate the factors associated with the risk of incomplete
occlusion (i.e., FD device failure), RRs and CIs were calculated using standard
statistical methods62.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The imaging data that support the findings of this study are available from the Centre for
Computational Imaging & Simulation Technologies in Biomedicine (www.cistib.org) at
the University of Leeds as coordinators of the @neurIST Consortium (www.aneurist.org).
Restrictions apply to the availability of these data, which were used under a Consortium
Agreement for the current study, and so are not publicly available. Bona fide researchers
can request access to the anatomical models and computational models via our
collaborative cloud-based research framework MULTI-X (www.multi-x.org). Researchers
can register and request access to research data and models developed by our and other
groups. Simulations pipelines can be launched on virtual machines using cloud-based
computing. Contact A. F. F. (a.frangi@leeds.ac.uk) for collaboration requests, which will
be answered within a week. Costs may be involved for cloud storage and
execution. Source Data are provided with this paper.
Code availability
All computational models used in this study have been described in previously published
works. The digital device implantation model is described in38. A standard Navier–Stokes
equation solver in ANSYS CFX v19.1 (Ansys Inc., Canonsburg, PA, USA) was used to
solve the flow problems. The clotting model is described in27 and the same model
parameters were used in this study. The flow model uses standard CFX solvers. Reference
implementations of the device implantation model and clotting model are available from
the authors upon a reasonable collaboration request. Contact A. F. F. (a.frangi@leeds.ac.
uk) for requests, which will be answered within a week.
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